The chairman and a senior member of the U.S. Senate Finance Committee on Friday issued a battery of questions to Gilead Sciences (GILD) about how it priced its blockbuster hepatitis C drug Sovaldi, adding to the chorus of objections to the product’s $1,000-per-pill price. The market was unfazed, however, with Gilead stock up a fraction in morning trading on the stock market today. Sens. Ron Wyden, D.-Ore., and Charles Grassley, R.-Iowa, published
Several key drugs from major drugmakers got endorsements from the European Medicines Agency (EMA) Friday, making commercial approval in the European Union’s enormous market much more likely. Bristol-Myers Squibb’s (BMY) hepatitis C drug daclatasvir, now branded Daklinza, was endorsed by the EMA’s Committee for Medicinal Products for Human Use (CHMP) for use in combination with other hep C drugs, notably Gilead Sciences’ (GILD) Sovaldi. Sovaldi and
It’s the middle of earnings season and expectations for investors are high. But it’s not just how well you do, but how well you do vs. expectations. Taser International (TASR), Gilead Sciences (GILD), Green Plains Renewable Energy (GPRE), Tesla Motors (TSLA) and SunPower (SPWR) are the top tech companies on the Estimate Beaters Screen of the Day. Taser beat Q4 earnings estimates by 116.7%. The security device company is slated to report Q1 results